ABCG2 and neoplasm: AZD9574 retained the selectivity and potency of AZD5305 (Table 4 and Fig. 5d), and dramatically regressed tumor growth in both subcutaneous and intracranial models.147 With low P-glycoprotein (P-gp)/breast cancer resistance protein (BCRP) driven efflux, AZD9574 displayed higher Kpuu in both rat (0.31) and monkey (0.79).